An IgA High-Titer Cold Agglutinin with an Unusual Blood Group Specificity within the Pr Complex

Vox Sanguinis ◽  
1973 ◽  
Vol 25 (1) ◽  
pp. 32-38 ◽  
Author(s):  
G. Garratty ◽  
L.D. Petz ◽  
I. Brodsky ◽  
H.H. Fudenberg
Vox Sanguinis ◽  
1973 ◽  
Vol 25 (1) ◽  
pp. 32-38 ◽  
Author(s):  
G. Garratty ◽  
L. D. Petz ◽  
I. Brodsky ◽  
H. H. Fudenberg

1978 ◽  
Vol 85 (4) ◽  
pp. 1453-1459 ◽  
Author(s):  
Richard Magous ◽  
Christian Lecou ◽  
Jean-Pierre Bali

Vox Sanguinis ◽  
1988 ◽  
Vol 55 (1) ◽  
pp. 53-54
Author(s):  
Eiji Kajii ◽  
Shigenori Ikemoto ◽  
Setsuko Suda ◽  
Yasusada Miura

Vox Sanguinis ◽  
1968 ◽  
Vol 14 (5) ◽  
pp. 321-333
Author(s):  
O. Prokop ◽  
G. Uhlenbruck ◽  
W. Köhler

Blood ◽  
1956 ◽  
Vol 11 (8) ◽  
pp. 700-707 ◽  
Author(s):  
LEONARD V. CROWLEY ◽  
BERTHA A. BOURONCLE

Abstract A significant proportion of patients with autoimmune hemolytic anemia form autoantibodies of blood group specificity, rather than nonspecific autoantibodies. Ashby survival studies suggest that in such cases properly selected blood, lacking the antigens against which autoantibody has been formed, can be transfused successfully. These concepts are important not only for a better understanding of the nature of autoantibodies, but also can be applied to the practical management of patients with autoimmune hemolytic anemia.


2007 ◽  
Vol 68 (3) ◽  
pp. 762-769 ◽  
Author(s):  
Kiran A. Kulkarni ◽  
Samiksha Katiyar ◽  
Avadhesha Surolia ◽  
Mamannamana Vijayan ◽  
Kaza Suguna

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 557-557 ◽  
Author(s):  
James C. Zimring ◽  
Gregory A. Hair ◽  
Traci E. Chadwick ◽  
Seema S. Deshpande ◽  
Kimberly M. Anderson ◽  
...  

Abstract Background: Transfusion of red blood cells (RBC) into patients with anti-donor RBC antibodies (crossmatch incompatible transfusion) can result in antibody mediated hemolysis. Less well appreciated is the ability of anti-RBC antibodies to specifically remove their target antigen from donor RBCs without compromising cell survival. This phenomenon has now been reported for the major clinically significant blood group antigens, including Rh, Kell, Kidd and Duffy. Although this has been described multiple times in humans, no mechanistic elucidation has been accomplished. In an effort to investigate the mechanism of this process, we describe the first animal model of non-hemolytic antibody induced RBC antigen loss. Methods: mHEL mice express the model antigen Hen Egg Lysozyme (HEL) as a cell surface protein on RBC. Since mHEL mice are on a C57BL/6 background, the mHEL antigen represents a single antigenic difference between donor RBC and recipient mice. Immunizing C57BL/6 mice with HEL/CFA results in the generation of high titer IgG anti-HEL responses rendering the mice crossmatch incompatible with mHEL RBC. This system was utilized to study the effects of transfusing mHEL RBC into crossmatch incompatible recipients. Results: Similar to the antibody induced antigen loss observed in humans, transfusion of donor mHEL RBC into crossmatch incompatible mice results in selective loss of HEL antigen from donor RBC without affecting other blood group antigens or reducing the circulatory lifespan of the donor RBC. In addition, recovered RBC that have lost their antigen have normal morphology. This process is antigen specific and occurs in mice that have received passive injections of anti-HEL antisera. A spleen is not required for antigen loss to occur. However, antigen loss does not occur in animals with a targeted deletion of the FcγIII receptor. Although polyclonal anti-HEL antisera consistently causes antigen loss, and IgG1 and IgG2b are the predominant subclasses of anti-HEL IgG in the antisera, no antigen loss is observed in response to purified monoclonal anti-HEL antibodies of the IgG1 and IgG2b subclass. Conclusion: These studies demonstrate that antibody induced antigen loss is a process that involves interaction of RBC, anti-RBC IgG and FcγIII receptors, thus providing mechanistic insight into the phenomenon of antigen loss during incompatible transfusion. The lack of antigen loss in response to monoclonal anti-HEL IgG1 or IgG2b suggests that antigen loss occurs in response to a minor IgG subtype in antisera, depends upon biological properties of the antibody (such as affinity), or that additional serum cofactors are involved.


2016 ◽  
Vol 94 (3) ◽  
pp. 224-230
Author(s):  
P. P. Ogurtsov ◽  
Elena I. Kukhareva

Aim. To estimate the prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for the achievement of sustained virologic response (SVR) to antiviral therapy (AVT) with the use ofpegylated interferon a-2 and ribavarin in patients with chronic genotype 1 hepatitis C (CHC-1). The secondary aim was to evaluate the influence of these genetic factors on the progress of hepatic fibrosis in case offailure of the above treatment. Materials and methods. A total of 146patients with CHC-1 were examined. We studied the RNA genotype of hepatitis C virus, blood group specificity, IL-28B gene polymorphism, and severity of hepatic fibrosis (puncture biopsies). Dynamics of hepatic fibrosis was followed up in 40 patients who failed to develop the virologic response. 20 control patients did not receive AVT. The multifactor significance criterion was used to identify the initial factor that produced the highest effect on SVR. Results. SVR was observed in 56.8% of the patients. Its efficiency was most significantly influenced by the combination of blood group specificity and interleukin 28B gene polymorphism (p=0.000024). Combination of blood group (0)1 with C/C or T/TIL-28B genotypes, A(II) with C/T or T/T, and B(III) with T/G was associated with SVR in 100, 88.2, and 94.4% cases respectively. It was absent in patients with blood group A(II) in combination with double-nucleotide substitution in rs8099917 of the IL-28B gene (TG and GG genotypes); these patients suffered progressive fibrosis. SVR occurred in 83.8% of the patients with blood group B(III). Conclusion. The knowledge of blood group in patients with CHC-1 and IL-28B gene polymorphism treated with the use of pegylated interferon a-2 and ribavarin allows to predict SVR with a probability of 100% in case of blood group 0(1) and C/C or T/T genotypes, 88.2% in case of blood group A(II) and single-nucleotide C>T substitution in rs8099917 locus of the IL-28B gene, 94.4% in case of blood group B(II) and single-nucleotide T>G substitution in the rs8099917 locus, 83.8% in case of blood group B(III). Treatment ofpatients with these genetic traits with antiviral drugs of direct action has no appreciable advances over treatment with AVT in combination with pegylated interferon a-2 and ribavarin (SVR above or around 85%). Patients with blood group A(II) and single- or double-nucleotide substitution in rs8099917 (TG or GG genotypes) have minimal chances to produce SVR to the above treatment. Simultaneous progression of hepatic fibrosis suggest that such therapy is undesirable in these cases. They should be regarded as main candidates for interferon-free therapy. Combination of blood group specificity and interleukin 28B gene polymorphism is a simple and reliable predictor of SVR and dynamics offibrosis in patients with CHC-1 receiving AVT with pegylated interferon a-2 and ribavirin; also, it may be an instrument of selection of patients for interferon-free therapy.


Sign in / Sign up

Export Citation Format

Share Document